Cloud-Clone launches anti-TUBb antibody for microtubule research

Cloud-Clone introduced a validated monoclonal antibody for tubulin-β (TUBb), a core microtubule protein used in cell, cancer and neuroscience research. The reagent is designed for Western blot, immunohistochemistry and immunofluorescence workflows across human and model-organism samples.

Why it matters: - Tubulin-β (TUBb) is a core building block of microtubules, which drive cell shape, intracellular transport and mitosis. - Research on TUBb spans basic biology, oncology and neuroscience, so a reliable antibody can affect multiple experimental workflows. - The new antibody is positioned as a tool for expression analysis, localization studies and post-translational modification research.

What happened: - Cloud-Clone introduced its anti-Tubulin Beta (TUBb) monoclonal antibody, Catalog No. CAB870Hu22. - The antibody is validated for Western blot, immunohistochemistry and immunofluorescence. - Cloud-Clone published the announcement on Sept. 16, 2026, from Houston.

The details: - TUBb pairs with α-tubulin to form stable heterodimers, the basic subunits of microtubules. - The protein is described as 455 amino acids and about 55 kDa. - TUBb is broadly expressed in the cytoplasm of eukaryotic cells and is highly conserved across species. - Microtubules built from TUBb show dynamic instability, meaning they rapidly assemble and disassemble. - TUBb supports structural integrity, long-distance intracellular transport and mitotic spindle formation. - TUBb also contributes to cilia and flagellar motility, cell migration and sensory functions. - The N-terminal nucleotide-binding domain contains the exchangeable GTP-binding site that drives polymerization and disassembly. - The intermediate domain is a binding site for paclitaxel, which stabilizes microtubules and blocks cancer-cell mitosis. - The C-terminal acidic domain binds motor proteins and carries modifications such as polyglutamylation and polyglycylation. - The human genome encodes at least seven TUBb isotypes, including βI and βIII. - βI is broadly expressed, while βIII is enriched in neurons and is linked in the release to neural development, nerve-injury repair, neurodegenerative disorders and tumour neural invasion. - The antibody is a mouse-derived monoclonal purified by Protein A+G affinity chromatography. - Cloud-Clone says the antibody recognizes human TUBb with minimal non-specific interactions. - The product is validated for human, rat, dog, bovine and zebrafish samples. - The antibody is supplied at 1 mg/mL in 0.01 M PBS with 0.05% Proclin-300 and 50% glycerol.

Between the lines: - The release frames TUBb as both a biology target and a translational target, especially for drug discovery and pathology. - Broad cross-species validation matters because it lets researchers compare microtubule biology across model systems without changing reagents. - The emphasis on loading-control use in Western blot suggests the antibody is meant to serve both routine normalization and direct target detection. - The product pitch centers on assay flexibility, which is a practical advantage for labs that move between protein quantification, tissue staining and imaging.

What's next: - Researchers can use CAB870Hu22 in Western blot, IHC and IF studies of cytoskeleton biology. - The release points to continued work on microtubule-directed cancer research, neurological disease studies and pathological analysis. - Cloud-Clone says the antibody is intended to support end-to-end workflows from molecular characterization to tissue-level profiling.

The bottom line: - Cloud-Clone is packaging TUBb as a high-value research target and its new antibody as a multi-assay reagent for labs studying microtubules, disease mechanisms and drug response. - More information is available in the company's announcement.